YUNITA KRISTIANA DEWI, 050911129 (2013) STUDI PENGGUNAAN SOMATOSTATIN DAN OKTREOTID PADA PASIEN SIROSIS HATI DENGAN HEMATEMESIS MELENA DI RUMKITAL Dr. RAMELAN SURABAYA. Skripsi thesis, UNIVERSITAS AIRLANGGA.

Preview	Text (ABSTRAK) gdlhub-gdl-s1-2014-dewiyunita-29568-7.abstr-t.pdf Download (49kB) | Preview
	Text (FULLTEXT) gdlhub-gdl-s1-2014-dewiyunita-29568-1.FULLTEXT.pdf Restricted to Registered users only Download (833kB) | Request a copy

Abstract

The aims of this study was to identify the somatostatin and octreotide profile, dose, route administrations; identify the appropriateness therapy with clinical data; identify the drug related problem. It was a retrospective study with descriptive analysis was done in 12 patients at High Care Unit Dr. Ramelan Naval Hospital during January 2010 to February 2013 who prefix diagnose cirrhosis hepatic with hematemesis melena and given somatostatin and octreotide therapy. The result showed that from 12 patients, somatostatin was given to 7 patients (58,33%) and octreotide was given to 5 patients (41,67%) The regimentation of somatostatin in cirrhosis hepatic patient with hematemesis melena is somatostatin 3 mg IV drips for 12 hours in 5 patients; somatostatin 3 mg IV bolus in 1 patient; somatostatin 3 mg IV bolus then somatostatin 3 mg IV drips for 12 hours in 1 patient. The regimentation of octreotide in cirrhosis hepatic patients with hematemesis melena is octreotide 0,2 mg IV drips for 8 hours in 1 patient; octreotide 0,1 mg IV bolus then octreotide 0,2 mg IV drips for 8 hours in 4 patients. Somatostatin and octreotide have the same time for 2-4 days to stop the bleeding. Potential interactions that occur between the octreotide and insulin of 7 patients (58.33%); octreotide and ciprofloxacin of 1 patient (8,33%); octreotide and metochlorpramide of 1 patient (8,33%). Potential adverse effects of hyperglycemia that occurs is in the amount of 2 patients (16.67%).

Actions (login required)

View Item